Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse

Herein, we aimed to report a diffuse large B cell lymphoma (DLBCL) case that had extensive cutaneous relapse with no skin involvement previously. A 59-year-old man presented to hospital in April 2014 with fatigue, anorexia, fever, and anemia. Cervical lymph node biopsy revealed CD20+, BCL2+, MUM1+,...

Full description

Saved in:
Bibliographic Details
Main Authors: Umit Yavuz Malkan, Gursel Gunes, Okan Yayar, Haluk Demiroglu
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2015/137682
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850170473755705344
author Umit Yavuz Malkan
Gursel Gunes
Okan Yayar
Haluk Demiroglu
author_facet Umit Yavuz Malkan
Gursel Gunes
Okan Yayar
Haluk Demiroglu
author_sort Umit Yavuz Malkan
collection DOAJ
description Herein, we aimed to report a diffuse large B cell lymphoma (DLBCL) case that had extensive cutaneous relapse with no skin involvement previously. A 59-year-old man presented to hospital in April 2014 with fatigue, anorexia, fever, and anemia. Cervical lymph node biopsy revealed CD20+, BCL2+, MUM1+, BCL6+ high grade B lymphoproliferative neoplasm. After FISH investigation, he was diagnosed as DLBCL. He was given 7 cycles of R-CHOP and achieved remission. However, in November 2014, he had emerging skin lesions that cover nearly all of his body. A control PET-CT revealed diffuse cutaneous involvement. CD20+, BCL2+, MUM1+, BCL6+ high grade B cell lymphoma infiltration was detected with skin biopsy. He was diagnosed as relapse lymphoma, so 2 cycles of R-DHAP were given. There was no treatment response; therefore, R-ICE regimen was started. The patient had achieved second complete remission and his skin lesions were completely regressed. The involvement of skin with CD20+ cells after 7 cycles of rituximab therapy favors that there is a rituximab resistant disease which tends to involve the skin. To conclude, DLBCL may relapse extensively with cutaneous involvement and the best treatment option in these patients is salvage chemotherapy followed by autologous peripheral blood stem cell transplantation.
format Article
id doaj-art-9d847ea915e246a8b894c47d0a1ded4f
institution OA Journals
issn 1687-9627
1687-9635
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Case Reports in Medicine
spelling doaj-art-9d847ea915e246a8b894c47d0a1ded4f2025-08-20T02:20:29ZengWileyCase Reports in Medicine1687-96271687-96352015-01-01201510.1155/2015/137682137682Diffuse Large B Cell Lymphoma with Extensive Cutaneous RelapseUmit Yavuz Malkan0Gursel Gunes1Okan Yayar2Haluk Demiroglu3Department of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyDepartment of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyDepartment of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyDepartment of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, TurkeyHerein, we aimed to report a diffuse large B cell lymphoma (DLBCL) case that had extensive cutaneous relapse with no skin involvement previously. A 59-year-old man presented to hospital in April 2014 with fatigue, anorexia, fever, and anemia. Cervical lymph node biopsy revealed CD20+, BCL2+, MUM1+, BCL6+ high grade B lymphoproliferative neoplasm. After FISH investigation, he was diagnosed as DLBCL. He was given 7 cycles of R-CHOP and achieved remission. However, in November 2014, he had emerging skin lesions that cover nearly all of his body. A control PET-CT revealed diffuse cutaneous involvement. CD20+, BCL2+, MUM1+, BCL6+ high grade B cell lymphoma infiltration was detected with skin biopsy. He was diagnosed as relapse lymphoma, so 2 cycles of R-DHAP were given. There was no treatment response; therefore, R-ICE regimen was started. The patient had achieved second complete remission and his skin lesions were completely regressed. The involvement of skin with CD20+ cells after 7 cycles of rituximab therapy favors that there is a rituximab resistant disease which tends to involve the skin. To conclude, DLBCL may relapse extensively with cutaneous involvement and the best treatment option in these patients is salvage chemotherapy followed by autologous peripheral blood stem cell transplantation.http://dx.doi.org/10.1155/2015/137682
spellingShingle Umit Yavuz Malkan
Gursel Gunes
Okan Yayar
Haluk Demiroglu
Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
Case Reports in Medicine
title Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
title_full Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
title_fullStr Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
title_full_unstemmed Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
title_short Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
title_sort diffuse large b cell lymphoma with extensive cutaneous relapse
url http://dx.doi.org/10.1155/2015/137682
work_keys_str_mv AT umityavuzmalkan diffuselargebcelllymphomawithextensivecutaneousrelapse
AT gurselgunes diffuselargebcelllymphomawithextensivecutaneousrelapse
AT okanyayar diffuselargebcelllymphomawithextensivecutaneousrelapse
AT halukdemiroglu diffuselargebcelllymphomawithextensivecutaneousrelapse